0001181431-13-046220.txt : 20130823 0001181431-13-046220.hdr.sgml : 20130823 20130823080029 ACCESSION NUMBER: 0001181431-13-046220 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20130821 FILED AS OF DATE: 20130823 DATE AS OF CHANGE: 20130823 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Aegerion Pharmaceuticals, Inc. CENTRAL INDEX KEY: 0001338042 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 202960116 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 101 MAIN STREET STREET 2: SUITE 1850 CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: (617) 500-7867 MAIL ADDRESS: STREET 1: 101 MAIN STREET STREET 2: SUITE 1850 CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: Aegerion Pharmaceuticals Inc DATE OF NAME CHANGE: 20050906 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Scheer David CENTRAL INDEX KEY: 0001378585 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-34921 FILM NUMBER: 131056245 MAIL ADDRESS: STREET 1: ACHILLION PHARMACEUTICALS STREET 2: 300 GEORGE STREET CITY: NEW HAVEN STATE: CT ZIP: 06511 4 1 rrd388969.xml FORM 4 X0306 4 2013-08-21 0 0001338042 Aegerion Pharmaceuticals, Inc. AEGR 0001378585 Scheer David C/O AEGERION PHARMACEUTICALS, INC. 101 MAIN STREET, SUITE 1850 CAMBRIDGE MA 02142 1 0 0 0 Common Stock 10000 D Common Stock 640154 I See Footnote Common Stock 2013-08-21 4 S 0 19600 84.572 D 620554 I See Footnote Common Stock 2013-08-21 4 S 0 400 85.068 D 620154 I See Footnote The Reporting Person, David Scheer, is the managing member of Scheer Investment Holdings VII LLC. Mr. Scheer disclaims beneficial ownership except to the extent of his proportionate pecuniary interest therein. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $84.00 to $84.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $85.03 to $85.08, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. /s/ Anne Marie Cook, attorney-in-fact 2013-08-23